Ipilimumab Biosimilar - Research Grade

Ipilimumab Biosimilar - Research Grade, Host: Humanized, IgG1 kappa

Target: CTLA-4.

Specificity: Detects human CTLA-4. This non-therapeutic antibody uses the same sequence as the therapeutic antibody Ipilimumab.

Purification method: This monoclonal antibody was purified using multi-step affinity chromatography methods such as Protein A or G depending on the species and isotype.

Background: Ipilimumab biosimilar is a recombinant, human monoclonal antibody that binds to the cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4). Ipilimumab biosimilar is an IgG1 kappa immunoglobulin with an approximate molecular weight of 148 kDa. Ipilimumab biosimilar is produced in mammalian (Chinese hamster ovary) cell culture.

Concentration: 1.0 - 5.0 mg/ml.

Formulation: Phosphate buffered saline (PBS) pH 7.2,with no carrier protein, potassium or preservatives added. BSA and Azide free.

Purity: >95% by SDS-PAGE and HPLC.

Endotoxin: ≤ 0.75 EU/mg as determined by the LAL method.

Use: Products are for research use only. Not for use in diagnostic or therapeutic procedures.

• SKU: ICH4025-5MG
• Manufacturer: Ichorbio
• Manufacturer SKU: ICH4025-5MG
• Package Unit: 5mg
• Quantity Unit: STK
• Reactivity: Human
• Clonality: Monoclonal
• Isotype: IgG1 kappa
• Host: Humanized